Trading November 9, 2026

Mineralys Therapeutics stock rises on 48-week lorundrostat data

Mineralys Therapeutics stock rises on 48-week lorundrostat data
Mineralys TherapeuticslorundrostathypertensionFDAclinical trialstock movementanalyst ratings

Mineralys Therapeutics shares rose almost 4.8% by midday after the company said its lead candidate, lorundrostat, maintained meaningful blood pressure reductions across 48 weeks in patients with uncontrolled or resistant hypertension. The data were presented Sunday at the American Heart Association Scientific Sessions 2026 in Chicago. In the Transform-HTN open-label extension, lorundrostat produced a 17.8 mmHg drop in automated office systolic blood pressure at week 48 versus the Launch-HTN baseline, and 56% of participants reached the recommended target of under 130 mmHg.

The clinical findings are especially relevant because the FDA has assigned a PDUFA target action date of December 22, 2026 to the lorundrostat New Drug Application—only weeks away—making the long-term durability and safety evidence an important component before the regulatory decision. The drug was well tolerated across the 36-week extension period, with no new clinically relevant safety signals, and 92% of the 632 enrolled patients completed the full 48 weeks of follow-up.

Analyst views remain split. Wainwright rates the stock Buy with a $56 price target. UBS, which began coverage in October with Neutral and a $29 target, has said the shares could stay range-bound without a pharmaceutical partnership or strong early prescription trends compared with rival treatments. The broader market was supportive: the S&P 500 added 2.3%, the Dow Jones gained 2.0%, and the Nasdaq rose 2.6%.

Taken together, lorundrostat’s durable clinical profile—now supported by the largest long-term hypertension trial of an aldosterone synthase inhibitor to date—along with a risk-on market backdrop and the upcoming FDA decision deadline, fueled the rise in Mineralys shares.

This article was produced with AI assistance and reviewed by an editor; additional details are available in the terms and conditions.

FractLab Unlock Your Edge A proprietary strategy built to surface hidden opportunities others miss. FractLab Trade with FractLab Multi-timeframe trend detection, accumulation filters and adaptive position scaling. FractLab Try it with a guarantee Full TradingView toolkit access. 30-day money back if it is not for you. Try